Status:
UNKNOWN
Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
Lead Sponsor:
Aarhus University Hospital
Collaborating Sponsors:
Odense University Hospital
Aalborg University Hospital
Conditions:
Lung Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
In non-small celled lung cancer (NSCLC) 10-15% of the patients harbor a mutation in the tumor's epidermal growth factor receptor (EGFR M+). This receptor is the target for treatment with erlotinib. Id...
Detailed Description
Background Non-small celled lung cancer (NSCLC) is one of the most common cancers in the world, and Denmark has one of the highest incidences of approximately 3800 new patients each year who are diagn...
Eligibility Criteria
Inclusion
- Lung cancer with a biopsy verified EGFR mutation eligible for treatment with erlotinib
Exclusion
- None
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 10 2020
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT02284633
Start Date
September 1 2014
End Date
June 10 2020
Last Update
November 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus, DK, Denmark, 8000